Home
Slides

Slide Tray

0 slides

View Empty Download

Return to Slide Library

Slides

Add Search Results to Slide Tray Search:

"pulmonary function"

Slides: 1–12 of 13

Add to tray Remove from tray

Effectiveness of Questionnaires and Clinical Prediction Rules

Presentation: Diagnosis and Treatment of Obstructive Sleep Apnea in Adults

Keywords: clinical prediction rules | detection | diagnosis | monitor | polysomnography | questionnaires | screening | strength of evidence | outcomes

Add to tray Remove from tray

Clinical Questions Addressed by the CER (1)

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Keywords: intermediate outcomes | health outcomes | pulmonary function | body composition | bone mineralization | pulmonary exacerbation | mortality risk | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH

Add to tray Remove from tray

Outcomes of Interest in Studies of rhGH Treatment of Patients With CF

Add to tray Remove from tray

rhGH Effects on Intermediate Outcomes in Controlled Trials: Pulmonary Function

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Keywords: absolute FVC | absolute FEV1 | percent predicted FVC | percent predicted FEV1 | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH

Add to tray Remove from tray

Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (1)

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Keywords: intermediate | outcome | end point | health outcome | mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH

Add to tray Remove from tray

Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (3)

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Keywords: regression | multivariate | univariate | anthropometrics | mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH

Add to tray Remove from tray

Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (4)

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Keywords: CF | HGH | HRQoL | QoL | anthropometrics | cystic fibrosis | health related quality of life | human growth hormone | mortality | multivariate | pulmonary function | quality of life | recombinant human growth hormone | regression | rhGH | univariate

Add to tray Remove from tray

Conclusions About Benefits and Harms (1)

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Keywords: hospitalization | weight | mortality | risk | bone mineral content | BMC | fracture | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH

Add to tray Remove from tray

Conclusions About Benefits and Harms (2)

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Keywords: CF | HGH | cystic fibrosis | health | human growth hormone | pulmonary function | recombinant human growth hormone | rhGH

Topic Refinement Process: UCONN/HH EPC Example (VII). Questions for Key Informants: How different is a study including people up to 23 years of age from a study limited to 18-year-olds? Consider this given the inverse linear relationship between human growth hormone efficacy and age, as well as the delayed growth and maturation inherent in this population. How readily do you feel we can combine certain end points (e.g., lean body mass measured by different methods [DEXA, skin folds, BIA] in same units) or amino acid catabolism measures (leucine vs. glutamine)?

Add to tray Remove from tray

Topic Refinement Process: UCONN/HH EPC Example (VII)

Presentation: Topic Refinement

Keywords: topic refinement | population | key informant

Topic Refinement Process: UCONN/HH EPC Example (VIII). Questions for Key Informants: In trials/studies that report multiple similar end points (like pulmonary function tests), which surrogate end points would be optimal (i.e., FEV1 percent vs. FEV1 absolute value)? Given the paucity of harms data, could harms data from patients without cystic fibrosis be used to inform the potential risks associated with human growth hormone therapy (i.e., how similar are patients with hypogonadism to those with cystic fibrosis and poor growth progression)? In particular, are you wary of using human growth hormone because of its risk of neoplasms?

Add to tray Remove from tray

Topic Refinement Process: UCONN/HH EPC Example (VIII)

Presentation: Topic Refinement

Keywords: topic refinement | key informant

$Key Questions (I). KQ 1: In patients with cystic fibrosis, does treatment with rhGH as an adjuvant to usual care improve intermediate outcomes, including pulmonary function (FEV percent and FEV1 absolute value), growth (height, weight, lean body mass, protein turnover), exercise tolerance, and bone mineralization, compared with usual care alone? KQ 2: In patients with cystic fibrosis, does treatment with rhGH as an adjuvant to usual care improve health outcomes, including frequency of required intravenous antibiotic treatments, frequency of hospitalization, quality of life, bone fracture or development of osteoporosis/osteopenia, or mortality, compared with usual care alone? KQ 3: In patients with cystic fibrosis, what is the strength of evidence that intermediate outcomes of pulmonary function, growth, and bone mineralization are associated with improvements in health outcomes of quality of life, bone fracture or development of osteoporosis/osteopenia, or mortality? KQ 4: In patients with cystic fibrosis, what is the frequency of nonmalignant serious adverse effects resulting from treatment with rhGH? Adverse effects of interest include, but are not limited to: glucose intolerance, diabetes, and hypoglycemia.$

Add to tray Remove from tray

Key Questions (I)

Presentation: Topic Refinement

Keywords: key question | PICOTS framework | analytic framework | health outcomes

Pages: [1] 2 Next